Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 59, showing 10 Applications out of 584 total, starting on record 31, ending on 40

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

31.

ECCT/25/04/03   PRETERM AFRICA STUDY
    Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa   
Principal Investigator(s)
1. Nayirat Mohamed
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
 
10-03-2026 View

32.

ECCT/25/05/08   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrudes Childrens Hospital (Nairobi City county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
05-03-2026 View

33.

ECCT/25/11/06   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr Maricianah Onono
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
 
05-03-2026 View

34.

ECCT/25/11/05   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr. Joshua Kimani
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
3. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
 
05-03-2026 View

35.

ECCT/25/08/05   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Dr. Isaac Tsikhutsu
Site(s) in Kenya
1. KEMRI WALTER REED KERICHO (Kericho county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrudes Childrens Hospital (Nairobi City county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
09-02-2026 View

36.

ECCT/25/11/03   RSV IMPACT TRIAL
    A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants.   
Principal Investigator(s)
1. Nancy A. Otieno
2. Evans M. Ogoti
Site(s) in Kenya
Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1)
 
09-02-2026 View

37.

ECCT/25/11/07   MK-8527 as HIV-1 PrEP
    Protocol Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. John Mark Ayallo
2. Kelvin Jerry Wandera
3. John Okanda
4. Joash Diemo
5. Tobias Odwar
6. Jacob Onyango
Site(s) in Kenya
1. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
2. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Center (URTC) (Kisumu county)
3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) (Nairobi City county)
 
09-02-2026 View

38.

ECCT/25/09/03   PRESERVE
    Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study   
Principal Investigator(s)
1. Angela Waweru
Site(s) in Kenya
Aga Khan University Hospital
 
09-02-2026 View

39.

ECCT/25/05/11   Sparkle study site-1406
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
03-02-2026 View

40.

ECCT/25/10/01   H06_04TP
    A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years   after vaccination in African children.   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
KEMRI CRC WRP KERICHO
 
01-02-2026 View